Federal Supply Schedule 36F79718D0403
Award Date
4/15/18
Last Date to Order
10/1/25
Federal Agency
Veterans Integrated Service Network 12
Awardee
Daiichi Sankyo, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The U.S. Department of Veterans Affairs (VA) awarded Daiichi Sankyo, Inc. a single-award Blanket Purchase Agreement (BPA) under the GSA Pharmaceuticals and Drugs Schedule. The BPA has a ceiling value of $1,378,620 and a period of performance from May 22, 2020 to May 21, 2025. The purpose of this contract is to provide the VA healthcare system with a stable supply of the specialty pharmaceutical product pexidartinib, marketed under the brand name TURALIO, for the treatment of tenosynovial...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center of the Department of Veterans Affairs (VA) to Daiichi Sankyo, Inc., a pharmaceutical manufacturer. The single-award BPA, valued at $80,206.95, provides a mechanism for VA healthcare facilities nationwide to efficiently procure the specialty drug pexidartinib (marketed as TURALIO) in various dosage forms. Pexidartinib is used to treat tenosynovial giant cell tumor, a rare disease, in eligible veteran patients....
The U.S. Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Blanket Purchase Agreement (BPA) to Takeda Pharmaceuticals America Inc. in July 2020. The $19,472,334.90 BPA, which falls under Takeda's General Services Administration (GSA) Pharmaceutical and Drugs Schedule contract, facilitates the streamlined procurement of critical specialty pharmaceutical products for the VA healthcare system. Key products under this BPA include CINRYZE and KALBITOR for...
Takeda Pharmaceuticals America, Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, holds a $360,141,120 multiple-award Federal Supply Schedule contract (36F79718D0586) with the U.S. Department of Veterans Affairs (VA) for Pharmaceuticals and Drugs (FSS-61-IB). As a prime contractor, Takeda leverages this IDV to efficiently supply critical oncology medications like ICLUSIG (ponatinib) and NINLARO (ixazomib) to VA medical facilities and Veterans...
The U.S. Department of Veterans Affairs (VA) awarded a Blanket Purchase Agreement (BPA) to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit manufacturer of pharmaceutical products, under the company's General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs. The single-award BPA, valued at over $13 million, is for the supply of the oncology medication ICLUSIG (ponatinib) to various VA Medical Centers and Veterans Integrated Service Networks (VISNs)...
Takeda Pharmaceuticals America Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, is the prime contractor on this General Services Administration (GSA) Indefinite Delivery Vehicle (IDV) contract to provide a range of specialty pharmaceutical products to various U.S. government agencies, including the Department of Veterans Affairs (VA), Department of Justice Bureau of Prisons, and Department of Defense.
The contract, which has a ceiling value of...
The U.S. Department of Veterans Affairs (VA) has awarded a multiple-award Federal Supply Schedule (FSS) contract to Kyowa Kirin, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the procurement of "Drugs, Pharmaceuticals, & Hematology Related Products." The contract has a ceiling value of $17,788,800 and a period of performance through September 29, 2027.
In addition to the FSS contract, the VA's National Acquisition Center has awarded a single-award Blanket...
The U.S. Department of Veterans Affairs (VA) has awarded a multiple award Federal Supply Schedule (FSS-61-IB) contract and a single award Blanket Purchase Agreement (BPA) to Sobi, Inc., a foreign-owned, for-profit pharmaceutical company, to provide pharmaceuticals and drug products.
The FSS contract, valued up to $78 million through July 2025, and the BPA, valued up to $11.75 million from October 2021 to September 2025, allow the VA to procure pharmaceuticals such as TEGSEDI, used to treat...
This Blanket Purchase Agreement (BPA) is a single-award indefinite delivery vehicle (IDV) held by Takeda Pharmaceuticals America, Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited. The BPA, valued at $123.5 million, was awarded by the Department of Veterans Affairs (VA) National Acquisition Center and is set to run through October 2025.
The primary purpose of this BPA is to provide the VA with a streamlined procurement mechanism for the specialty...
This Federal Supply Schedule (FSS) contract with the U.S. Department of Veterans Affairs (VA) was awarded to Taiho Oncology, Inc., a foreign-owned, for-profit manufacturer of goods. The contract, valued at a ceiling of $119,747,310.00, is for the supply of Drugs, Pharmaceuticals, & Hematology Related Products (FSS-61-IB) and has a period of performance through March 31, 2027.
As a Federal Supply Schedule contract, this vehicle allows the VA and other federal agencies to procure the...